E-mail: brychtova.yvona@fnbrno.cz
Odborné práce publikované na Linkos.cz
Přehled odborných textů publikovaných autorem na portálu Linkos.cz. Jsou zde uvedeny knihy a brožury, články v Klinické onkologii, tuzemská abstrakta z databáze abstrakt a další texty. Rejstřík není v žádném případě úplným autorským rejstříkem, protože jsou zde uvedeny pouze texty zveřejněné na portálu Linkos.cz.
Publikované knihy
Publikovaná abstrakta
- ACUTE MYELOID LEUKEMIAS WITH RECURRENT GENETIC ABNORMALITIES: FREQUENT ASSESSMENT OF MINIMAL RESIDUAL DISEASE AND TREATMENT OF MOLECULAR RELAPSE
- ALLOGENEIC STEM CELL TRANSPLANTATIONS AFTER REDUCED INTENSITY CONDITIONING REGIMEN FLUDARABIN, BUSULFAN AND ATG (FRESENIUS)
- ANALYSIS OF MERKEL CELL POLYOMAVIRUS PROGNOSTIC SIGNIFICANCE IN CHRONIC LYMPHOCYTIC LEUKEMIA
- ANALYSIS OF POTENTIALLY BICLONAL CLL PATIENTS WITH TWO OR THREE PRODUCTIVE IGH REARRANGEMENTS
- AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN ADULT ACUTE LYMPHOBLASTIC LEUKEMIA: STILL NOT OUT OF FASHION
- BIOLOGICAL AND CLINICAL RELEVANCE OF MIRNAS INDUCED IN CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) CELLS DURING ADMINISTRATION OF THERAPY IN VIVO AND IN VITRO
- BONE MARROW VERSUS PERIPHERAL BLOOD: COMPARISON OF THE CHIMERISM ANALYSIS
- CD52 ANTIGEN IS EXPRESSED AT DIFFERENT INTENSITIES ON TUMOR CELLS OF PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA, SMALL LYMPHOCYTIC LYMPHOMA, MANTLE CELL LYMPHOMA AND ON CD34+ CELLS
- Clinical Outcome of B-Cell Chronic Lymphocytic Leukemia Following Alemtuzumab Therapy: Retrospective Study within Various Cytogenetic Risk Categories
- Clonal Evolution and Therapy Related Selection Of TP53 Mutations In Chronic Lymphocytic Leukemia Patients
- Clonal Evolution of Malignant Populations In Potentially Biclonal Chronic Lymphocytic Leukemia Patients
- Constitutive Activation of STAT1 and STAT3 Proteins on Serine and Tyrosine Residues Were Found in Majority of CLL
- CONSTITUTIVE ACTIVATION OF STAT1 AND STAT3 PROTEINS WITHOUT INTERFERON INDUCIBILITY: RELEVANCE TO THERAPY IN IGVH-UNMUTATED CLL PATIENTS
- DEEP SEQUENCING IDENTIFIES TP53 MUTATIONS BEFORE THEIR CLONAL SELECTION BY THERAPY IN CHRONIC LYMPHOCYTIC LEUKEMIA
- Defects of ATM Gene Involving Mutation Lead to Complete Elimination of ATM Function in Chronic Lymphocytic Leukemia
- DEFINITION AND VALIDATION OF NOVEL PROGNOSTIC MARKERS IN B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA
- DELETION OF 14Q IN COHORT OF 560 PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKAEMIA
- Detail Characterization of 22q11 Deletion and Mir-650 Role in CLL Patients
- Detection and Treatment of Molecular Relapse in Acute Myeloid Leukemia with RUNX1, CBFB or MLL Gene Translocations. Frequent Quantitative Monitoring of Molecular Markers in Different Compartments and Correlation with WT1 Gene Expression.
- DETECTION OF MINIMAL RESIDUAL DISEASE IN PATIENT WITH CHRONIC LYMPHOCYTIC LEUKEMIA USING BOTH FOUR-COLOR AND EIGHT-COLOR FLOW CYTOMETRY AND QUANTITATIVE REAL TIME PCR APPROACH
- Detection of Molecular Relapse of AML by Very Frequent Quantitative Monitoring of Different Molecular Markers (Fusion Transcripts and WT1) in Different Compartments (Peripheral Blood-PB, Bone Marrow-BM, and Selected CD34+ Bone Marrow Cells) and Its..
- DETECTION OF MOLECULAR RELAPSE OF AML BY VERY FREQUENT QUANTITATIVE MONITORING OF DIFFERENT MOLECULAR MARKERS IN DIFFERENT COMPARTMENTS AND ITS TREATMENT WITH CHEMOTHERAPY OR GEMTUZUMAB OZOGAMICIN
- EFFICACY AND TOXICITY OF THE FLAMSA/RIC REGIMEN IN 40 PATIENTS WITH HIGH-RISK AML: A SINGLE CENTRE EXPERIENCE
- ELIMINATION OF MUTATED P53 PROTEIN AND INDUCTION OF P53 DOWNSTREAM GENES IN CHRONIC LYMPHOCYTIC LEUKEMIA CELLS USING PRIMA-1MET
- Gene-Expression Profile of Steroid-Refractory Acute Graft-Versus-Host Disease
- Gene-Expression Profiling of Graft-Versus-Host Disease by Oligonucleotide Microarrays
- GENOMIC COPY NUMBER ALTERATIONS IN HIGH-RISK CLL PATIENTS HARBORING TP53 DEFECTS: INSIGHTS FROM CONSECUTIVE INVESTIGATIONS
- HIGH EFFICACY OF PULSE CYCLOPHOSPHAMIDE IN CORTICOSTEROID-REFRACTORY LIVER GRAFT-VERSUS-HOST DISEASE
- High Expression of LAG3, LPL and ZAP-70 Genes in B-CLL Strongly Correlates with Unmutated IgVH and Early Therapy Requirement
- CHARACTERIZATION OF P53 AND ATM ABNORMALITIES IN B-CLL PATIENTS
- CHRONIC LYMPHOCYTIC LEUKEMIA CELLS ARE HIGHLY SUSCEPTIBLE TO DIRECT INHIBITION OF CHECKPOINT KINASE 1
- IS NONMYELOABLATIVE TRANSPLANT SUFFICIENT TO CURE CHRONIC MYELOID LEUKEMIA?
- JAK2 Mutation and Additional Thrombophilic Markers Predispose to Thrombosis in Myeloproliferative Diseases with Thrombocythemia
- JAK2 MUTATION AND AN ADDITIONAL THROMBOPHILIC STATE ARE MAJOR PROTHROMBOTIC RISK FACTORS IN MYELOPROLIFERATIONS WITH THROMBOCYTHEMIA – DATA FROM A REGISTRY OF ANAGRELIDE-TREATED PATIENTS
- Léčba akutní myeloidní leukémie u nemocných ve věku nad 60 let. Srovnání kurativní a paliativní léčby
- LONG-TERM RESULTS OF REDUCED-INTENSITY ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR 1ST CHRONIC PHASE CML
- LOW-DOSE FCR IN ELDERLY/COMORBID PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): UPDATED RESULTS OF PROJECT Q-LITE BY CZECH CLL STUDY GROUP
- LOW-DOSE FCR IN THE TREATMENT OF ELDERLY/COMORBID PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL): UPDATED RESULTS OF PROJECT Q-LITE BY CZECH CLL STUDY GROUP
- Low-Dose FCR Is a Safe and Effective Treatment Option for Elderly/Comorbid Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Updated Results of Project Q-Lite By Czech CLL Study Group
- LOW-DOSE FLUDARABINE AND CYCLOPHOSPHAMIDE COMBINED WITH RITUXIMAB IN THE TREATMENT OF ELDERLY/COMORBID PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA: PROJECT Q-LITE OF CZECH CLL STUDY GROUP
- Low-Dose Fludarabine and Cyclophosphamide Combined with Rituximab In the Treatment of Elderly/Comorbid Patients with chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): Preliminary Results of Project Q-Lite by Czech CLL Study Group
- Microrna-34a As a Marker for Fludarabine Resistance and Impairment of p53-Pathway in Chronic Lymphocytic Leukemia
- MICRORNA-34A IS SIGNIFICANTLY DOWN-REGULATED IN B-CLL PATIENTS WITH P53 ABNORMALITIES
- MICRORNAS EXPRESSION PATTERN IN AGGRESSIVE SUBTYPE OF CHRONIC LYMPHOCYTIC LEUKEMIA
- MISSENSE MUTATIONS LOCATED IN STRUCTURAL P53 DNA-BINDING MOTIFS ARE ASSOCIATED WITH EXTREMELY POOR SURVIVAL IN CHRONIC LYMPHOCYTIC LEUKEMIA
- MOLECULAR ANALYSIS OF IGVH GENE MUTATIONAL STATUS AS A PROGNOSTIC FACTOR IN B – CLL WITHIN CZECH PATIENTS
- MONITORING OF THE STATUS OF BOTH P53 ALLELES IN PATIENTS WITH B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA - RELEVANCE TO PROGNOSIS AND TREATMENT
- MORBIDITY AND MORTALITY WITH NONMYELOABLATIVE COMPARED TO MYELOABLATIVE CONDITIONING BEFORE RELATED STEM CELL TRANSPLANTATION
- MUTATION STATUS OF ATM GENE IN CLL PATIENTS HARBORING DELETION 11Q OR TP53 DEFECT
- Mutational Analysis of Mir-29 Family Members in Chronic Lymphocytic Leukemia
- MUTATIONS IN THE TP53 GENE SHOW FEATURES OF SOMATIC HYPERMUTATION PROCESS WITH PROMINENT DIFFERENCE BETWEEN IGHV MUTATED AND UNMUTATED CHRONIC LYMPHOCYTIC LEUKEMIA
- NEW PROGNOSTIC MARKERS OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN THE EVERYDAY HEMATOLOGICAL PRACTICE. A MULTICENTER ANALYSIS
- Ofatumumab Added To Dexamethasone In Patients With Relapsed Or Refractory Chronic Lymphocytic Leukemia. Results From a Phase II Study Of The Czech Leukemia Study Group For Life
- PRESENCE OF HETEROZYGOUS ATM DELETION MAY NOT BE CRITICAL FOR THE RESPONSE OF CLL CELLS TO FLUDARABINE
- PROGNOSIS OF RELAPSED CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AFTER COMBINED FLUDARABINE, CYCLOPHOSPHAMIDE AND RITUXIMAB (FCR) TREATMENT
- Prognostic Impact of NOTCH1 Hotspot Mutation in TP53-Mutated Patients with Chronic Lymphocytic Leukemia
- PROGNOSTICKÝ VÝZNAM HOT SPOT MUTACE GENU NOTCH1 U PACIENTŮ S CHRONICKOU LYMFOCYTÁRNÍ LEUKEMIÍ A SOUVISLOST S MOLEKULÁRNĚ BIOLOGICKÝMI MARKERY ONEMOCNĚNÍ
- Prognostický význam mutačního stavu genu TP53 u pacientů s B-buněčnou chronickou lymfocytární leukémií – význam monitorováni obou alel.
- Přítomnost heterozygotní delece ATM nedeterminuje odpověď CLL buněk na fludarabin
- QUANTITATIVE DETECTION OF MINIMAL RESIDUAL DISEASE IN B-CELL CHRONIC LYMPHOCYTIC LEUKEMIA USING LNA-MODIFIED TAQ-MAN PROBES AND IGH-RQ PCR
- REARRANGEMENT OF LAMBDA IMMUNOGLOBULIN LIGHT CHAIN IN CLL IS COUPLED WITH MIRNA-650 EXPRESSION
- RELATIONSHIP BETWEEN THERAPY AND CLONAL EVOLUTION OF TP53 ABNORMALITIES IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
- RITUXIMAB IN COMBINATION WITH HIGH-DOSE DEXAMETHASONE: AN EFFECTIVE TREATMENT OPTION FOR PATIENTS WITH RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
- Rituximab In Combination with High-Dose Dexamethasone: An Effective Treatment Option for Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia
- Rituximab Sensitizes B-CLL Cells with Inactivated p53 to Fludarabine.
- RITUXIMAB SENSITIZES SOME B-CLL SAMPLES TO FLUDARABINE AND CHLORAMBUCIL IN VITRO, REGARDLESS OF P53/ATM STATUS
- Role of p53 Gene Mutation Type in B-CLL Prognosis
- SENSITIZATION OF LEUKEMIC CELLS TO FLUDARABINE BY MONOCLONAL ANTIBODY RITUXIMAB - IDENTIFICATION OF RESPONSIBLE GENES
- Sequence Variations in miRNA Genes Are Common and May Affect Their Expression in Patients with Chronic Lymphocytic Leukemia
- SF3B1 Mutations Frequently Occur With Both ATM Mutations and TP53 Mutations In CLL Patients
- Single Cell Analysis of IG Genes in CLL: Cases with Multiple IGH Rearrangements Are Constituted of Several Independent Clones Even When Indistinguishable By Flow Cytometry
- Single Cell Analysis Proves the Coexistence of NOTCH1 and TP53 Mutations within the Same Cancer Cells in Patients with Chronic Lymphocytic Leukemia
- Sledování defektů ve fosforylaci STAT1, STAT3 proteinů a jejich význam pro stanovení prognózy u CLL pacientů
- Sledování exprese vybraných genů u pacientů s B-buněčnou chronickou lymfocytární leukémií – záchyt změny leukemického klonu vlivem terapie
- Stanovení exprese ZAP-70 metodou kvantitativní cytometrie, korelace s mutačním stavem IgVH a expresí CD38 u pacientů s diagnózou B-CLL
- STUDIUM KLONÁLNÍ KOMPOZICE CHRONICKÉ LYMFOCYTÁRNÍ LEUKEMIE S VÍCEČETNÝMI IMUNOGLOBULINOVÝMI PŘESTAVBAMI NA ÚROVNI JEDNOTLIVÝCH BUNĚK
- STUDIUM SELEKCE NEPŘÍZNIVÝCH GENOMICKÝCH ABNORMALIT V RELAPSU CHRONICKÉ LYMFOCYTÁRNÍ LEUKEMIE
- Terapeutické monoklonální protilátky senzitivizují in vitro některé B-CLL vzorky s aberacemi genu TP53 k fludarabinu a chlorambucilu.
- THE EXPRESSION OF A SINGLE MICRORNA - MIR-34A – IS A RELIABLE MARKER FOR IMPAIRMENT OF P53-PATHWAY IN CHRONIC LYMPHOCYTIC LEUKEMIA
- THE IMPACT OF SPECIFIC MUTATIONS IN TP53 GENE ON THE RESULTS OF ALEMTUZUMAB THERAPY IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS
- The Regulation, Targets and Clinical Relevance of Microrna Mir-650 in Chronic Lymphocytic Leukemia (CLL)
- Thrombosis in MPN with Thrombocythemia Is Associated with Higher Platelet Count At the Time of the Event: Data From the Czech Registry of Patients Treated with Anagrelide
- TRANSLOCATION IS A FREQUENT MECHANISM FOR 17P DELETION IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
- TREATMENT OF PHILADELPHIA-POSITIVE ADULT ACUTE LYMPHOBLASTIC LEUKEMIA IN REAL LIFE: EXPERIENCE OF ONE CENTRE
- TUMOR DYNAMICS OF CHRONIC LYMPHOCYTIC LEUKEMIA CASES WITH MULTIPLE PRODUCTIVE IGHV-IGHD-IGHJ REARRANGEMENTS
- WHAT CAN WE CURRENTLY LEARN FROM NEW PROGNOSTIC MARKERS OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) IN THE EVERYDAY HAEMATOLOGICAL PRACTICE?
- WHAT DO WE KNOW ABOUT THE REAL INCIDENCE OF CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) AND WHERE AND HOW ARE THE PATIENTS WITH CLL TREATED?
